References
- Bays, H.E., et al., 2014. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity, 22 (4), 1042–1049.
- Ghezzi, C., Loo, D.D.F., and Wright, E.M., 2018. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia, 61 (10), 2087–2097.
- Good, S.S., and Miranda, P.D., 1992. Species differences in the metabolism and disposition of antiviral nucleoside analogues: 2. Zidovudine. Antiviral chemistry and chemotherapy, 3 (2), 65–77.
- He, Y.L., et al., 2019. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes, obesity and metabolism, 21 (6), 1311–1321.
- Mamidi, R.N., et al., 2014. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug metabolism and disposition: the biological fate of chemicals, 42 (5), 903–912.
- Miranda, P.D., Burnette, T.C., and Good, S.S., 1989. Tissue distribution and metabolic disposition of zidovudine in rats. Drug metabolism and disposition, 18, 315–320.
- Mukai, M., et al., 2015. Species and sex differences in propofol glucuronidation in liver microsomes of humans, monkeys, rats and mice. Pharmazie, 70, 466–470.
- Ndefo, U.A., et al., 2015. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P & T, 4o (6), 364–368.
- Obermeier, M., et al., 2010. In vitro characterization and pharmacokinetics of dapagliflozin (BSM-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug metabolism and disposition, 38 (3), 405–414.
- Pellock, S.J., and Redinbo, M.R., 2017. Glucuronides in the gut: Sugar-driven symbioses between microbe and host. The journal of biological chemistry, 292 (21), 8569–8576.
- Safety Testing of Drug Metabolites, 2016. Guidance for industry. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER).
- Sigafoos, J.F., et al., 2012. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug metabolism and disposition: the biological fate of chemicals, 40 (11), 2090–2012.
- Turk, E., et al., 1991. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature, 350 (6316), 354–356.
- Zell, M., et al., 2014. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica; the fate of foreign compounds in biological systems, 44 (4), 369–378.